Both proteasomes and lysosomes degrade the activated erythropoietin receptor
Pierre Walrafen(Hôpital Cochin), Patrick Mayeux(Université Paris Cité), Stany Chrétien(Inserm), Frédèrique Verdier(Centre National de la Recherche Scientifique), Zahra Kadri(CEA Paris-Saclay - Etablissement de Fontenay-aux-roses), Catherine Lacombe(Centre National de la Recherche Scientifique)
Cited by 177
Related Papers
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
|Blood|2015|383
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
|Haematologica|2009|316